Suven Life Sciences Limited

Suven Life Sciences has secured one product patent each in Canada, Europe and Hong Kong for its new chemical entities being developed for treatment of neurodegenerative diseases, the company said in an exchange filing on Thursday. The patents in Canada, Europe and Hong Kong are valid until 2030, 2032 and 2032, respectively. With this, the company has a total of 24 patents granted in Canada, 22 in Europe and 21 in Hong Kong. Products out of these inventions may be out-licensed at various phases of clinical development, it said. Shares of Suven Life were up 2.16 per cent at ₹196.05 on the NSE.